Objects
Keats, Julian, Haber, P, Carolyn, D, Gregory, D, Loveday, S, Tawil, V, Krahn, M, Thein, H-H, Micallef, Michelle, Dunlop, Adrian, Grebely, Jason, Hazelwood, Susan, Everingham, Hope, Shrestha, Nikrant, Jones, Tracey, Bath, Nicky, Treloar, Carly, Dore, Gregory J.. Elsevier; 2015. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Fortier, Emmanuel, Alavi, Maryam, Bath, Nicky, Haber, Paul S., Dore, Gregory J., Grebely, Jason, ETHOS Study Group,, Bruneau, Julie, Micallef, Michelle, Perram, Jacinta, Sockalingam, Sanjeev, Dunlop, Adrian J., Balcomb, Annie C., Day, Carolyn A., Treloar, Carla. Lippincott Williams & Wilkins; 2017. Depression, anxiety, and stress among people with chronic hepatitis C virus infection and a history of injecting drug use in New South Wales, Australia.
Valerio, Heather, Alavi, Maryam, Read, Phillip, Marks, Philippa, Degenhardt, Louisa, Hayllar, Jeremy, Reid, David, Gorton, Carla, Lam, Thao, Dore, Gregory J., Grebely, Jason, Silk, David, Treloar, Carla, Martinello, Marianne, Milat, Andrew, Dunlop, Adrian, Holden, Jo, Henderson, Charles, Amin, Janaki. Oxford University Press; 2021. Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Midgard, Håvard, Hajarizadeh, Behzad, Hellard, Margaret, Robaeys, Geert, Thurnheer, Marcia C., Weltman, Martin, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Dore, Gregory J., Dalgard, Olav, Grebely, Jason, Cunningham, Evan B., Conway, Brian, Backmund, Markus, Bruggmann, Philip, Bruneau, Julie, Bourgeois, Stefan, Dunlop, Adrian, Foster, Graham R.. Elsevier; 2017. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study.
Cunningham, Evan B., Hajarizadeh, Behzad, Swan, Tracy, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Dalgard, Olav, Thurnheer, Maria Christine, Dore, Gregory J., Grebely, Jason, Amin, Janaki, Hellard, Margaret, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert. BioMed Central; 2017. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa. Elsevier; 2022. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Wheeler, Alice, Valerio, Heather, Matthews, Gail V., Dunlop, Adrian J., Gorton, Carla, Hayllar, Jeremy, Alavi, Maryam, Murray, Carolyn, Marks, Phillipa, Silk, David, Degenhardt, Louisa, Dore, Gregory J., Cunningham, Evan B., Grebely, Jason, Martinello, Marianne, Barocas, Joshua A., Colledge-Frisby, Samantha, Treloar, Carla, Amin, Janaki, Henderson, Charles, Read, Phillip. Elsevier; 2022. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study.
Treloar, Carla, Rance, Jake, Loveday, Stuart, Micallef, Michelle, Thein, Hla-Hla, Alavi, Maryam, Marks, Pip, Jones, Ineke, Siriragavan, Sharmila, Tamaddoni, Mahshid, Abbott, P., Balcomb, Annie, Haber, Paul, van Beek, Ingrid, Dunlop, Adrian, Phung, Nghi, Weltman, Martin, Doab, Anna, Hazelwood, Sussan, Lam, Thao, Petersen, Jamieleigh, Sevehon, Alison, Taylor, Ann, Bath, Nicky, D'Aquino, Fiona, Evangelista, Lucia, Pollard, Emma, Wrightson, Julieanne, Day, Carolyn, Dore, Gregory, Grebely, Jason, Honey, Claire, Krahn, Murray, Lodge, Mike. Elsevier; 2014. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.
Grebely, Jason, Alavi, Maryam, Haber, Paul S., Dore, Gregory J., Micallef, Michelle, Dunlop, Adrian J., Balcomb, Anne C., Phung, Nghi, Weltman, Martin D., Day, Carolyn A., Treloar, Carla, Bath, Nicky. Wiley-Blackwell; 2016. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Grebely, Jason, Dalgard, Olav, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Bruneau, Julie, Midgard, Håvard, Cunningham, Evan B., , , , Hajarizadeh, Behzad, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy. Elsevier; 2017. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
Fortier, Emmanuel, Alavi, Maryam, Bruneau, Julie, Grebely, Jason, , Micallef, Michelle, Dunlop, Adrian J., Balcomb, Annie C., Day, Carolyn A., Treloar, Carla, Bath, Nicky, Haber, Paul S., Dore, Greory J.. Elsevier; 2015. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: the ETHOS study.
Alavi, Maryam, Grebely, Jason, Micallef, Michelle, Dunlop, Adrian J., Balcomb, Annie C., Day, Carolyn A., Treloar, Carla, Bath, Nicky, Haber, Paul S., Dore, Gregory J.. Oxford University Press; 2013. Assessment and treatment of Hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Conway, Anna, Stevens, Annabelle, Read, Phillip, Starr, Mitchell, Catlett, Beth, Cunningham, Philip, Grebely, Jason, Murray, Carolyn, Prain, Bianca, Power, Cherie, McNulty, Anna, Carrington, Nigel, Lu, Heng, Kingsland, Melanie, McGrath, Colette. Oxford University Press; 2023. Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study.
Cheng, Qinglu, Cunningham, Evan B., Hellard, Margaret, Bruggmann, Philip, Marks, Philippa, Lacombe, Karine, Stedman, Catherine, Read, Phillip, Hajarizadeh, Behzad, Dunlop, Adrian J., Conway, Brian, Feld, Jordan J., Shih, Sophy, Dore, Gregory J., Grebely, Jason, SIMPLIFY and D3FEAT Study Groups,, Amin, Janaki, Bruneau, Julie, Artenie, Adelina A., Powis, Jeff, Litwin, Alain H., Cooper, Curtis, Dalgard, Olav. Elsevier; 2023. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Carrington, Nigel, Conway, Anna, Holden, Joanne, Keen, Phillip, Kingsland, Melanie, Lu, Heng, Power, Cherie, Read, Phillip, Murray, Carolyn, McNulty, Anna, Cunningham, Philip, Grebely, Jason, Starr, Mitchell, Catlett, Beth, Stevens, Annabelle, Prain, Bianca, McGrath, Colette, Causer, Louise, Guy, Rebecca. BioMed Central (BMC); 2024. Testing, diagnosis, and treatment following the implementation of a program to provide dried blood spot testing for HIV and hepatitis C infections: the NSW DBS Pilot.
Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert. Elsevier; 2024. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.